Technical Analysis for TYRA - Tyra Biosciences, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| C | 17.28 | 8.07% | 1.29 |
TYRA closed up 8.07 percent on Monday, July 1, 2024, on 88 percent of normal volume. It ran into resistance at its 50 day moving average. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Resistance | Bearish | 0.00% | |
| Stochastic Buy Signal | Bullish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| 200 DMA Support | Bullish | 8.07% | |
| Pocket Pivot | Bullish Swing Setup | 8.07% | |
| Volume Surge | Other | 8.07% | |
| Wide Bands | Range Expansion | 8.07% | |
| Oversold Stochastic | Weakness | 8.07% | |
| 200 DMA Support | Bullish | 11.84% |
| Alert | Time |
|---|---|
| Up 1 ATR | about 5 hours ago |
| Up 5% | about 6 hours ago |
| Rose Above 10 DMA | about 6 hours ago |
| 60 Minute Opening Range Breakout | about 8 hours ago |
| Up 3% | about 10 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 08/08/2024
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2-related cancers, FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Biology Tumor Cell Biology Tyrosine Kinase Receptors Bladder Cancer Fibroblast Growth Factor Fibroblast Growth Factor Receptor Preclinical Stage Biopharmaceutical Clusters Of Differentiation
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Biology Tumor Cell Biology Tyrosine Kinase Receptors Bladder Cancer Fibroblast Growth Factor Fibroblast Growth Factor Receptor Preclinical Stage Biopharmaceutical Clusters Of Differentiation
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 21.14 |
| 52 Week Low | 10.47 |
| Average Volume | 169,059 |
| 200-Day Moving Average | 15.44 |
| 50-Day Moving Average | 17.53 |
| 20-Day Moving Average | 17.94 |
| 10-Day Moving Average | 16.76 |
| Average True Range | 1.12 |
| RSI (14) | 48.98 |
| ADX | 20.05 |
| +DI | 22.09 |
| -DI | 22.68 |
| Chandelier Exit (Long, 3 ATRs) | 17.77 |
| Chandelier Exit (Short, 3 ATRs) | 18.62 |
| Upper Bollinger Bands | 21.00 |
| Lower Bollinger Band | 14.88 |
| Percent B (%b) | 0.39 |
| BandWidth | 34.15 |
| MACD Line | -0.39 |
| MACD Signal Line | -0.14 |
| MACD Histogram | -0.248 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 20.42 | ||||
| Resistance 3 (R3) | 20.18 | 18.90 | 19.89 | ||
| Resistance 2 (R2) | 18.90 | 18.10 | 19.02 | 19.72 | |
| Resistance 1 (R1) | 18.09 | 17.61 | 18.50 | 18.33 | 19.54 |
| Pivot Point | 16.81 | 16.81 | 17.01 | 16.93 | 16.81 |
| Support 1 (S1) | 16.00 | 16.01 | 16.41 | 16.24 | 15.02 |
| Support 2 (S2) | 14.72 | 15.52 | 14.84 | 14.84 | |
| Support 3 (S3) | 13.91 | 14.72 | 14.67 | ||
| Support 4 (S4) | 14.15 |
